Controls N (%) | Cases N (%) | OR (95% CI)* | aOR (95% CI)† | |
No lag (n=93 508) | ||||
No exposure | 48 802 (51.67) | 502 (50.91) | 1.00 (Ref) | 1.00 (Ref) |
Ever exposure (µmol/L)‡ | 44 720 (48.33) | 484 (49.09) | 1.03 (0.91 to 1.17) | 1.07 (0.93 to 1.22) |
<23.87 | 9 030 (10.73) | 119 (12.07) | 1.20 (0.97 to 1.48) | 1.20 (0.97 to 1.49) |
23.87–102.90 | 10 044 (10.86) | 111 (11.26) | 1.02 (0.82 to 1.28) | 1.04 (0.83 to 1.20) |
>102.90 | 24 746 () | 254 (25.76) | 0.98 (0.84 to 1.15) | 1.02 (0.87 to 1.20) |
Test for trend | 1.00 (0.98 to 1.01) | 1.00 (0.99 to 1.02) | ||
5-year lag | ||||
No exposure | 53 250 (57.55) | 558 (56.59) | 1.00 (Ref) | 1.00 (Ref) |
Ever exposure (µmol/L)‡ | 39 272 (42.45) | 428 (43.41) | 1.05 (0.92 to 1.19) | 1.08 (0.94 to 1.24) |
<23.87 | 11 337 (12.25) | 128 (12.98) | 1.08 (0.89 to 1.32) | 1.14 (0.93 to 1.39) |
23.87–102.90 | 11 365 (12.28) | 119 (12.07) | 1.01 (0.82 to 1.23) | 1.05 (0.85 to 1.29) |
>102.90 | 16 570 (17.91) | 181 (18.36) | 1.05 (0.89 to 1.24) | 1.06 (0.89 to 1.27) |
Test for trend | 1.00 (0.99 to 1.01) | 1.01 (0.98 to 1.04) | ||
10-year lag | ||||
No exposure | 55 274 (59.74) | 575 (58.32) | 1.00 (Ref) | 1.00 (Ref) |
Ever exposure (µmol/l)‡ | 37 248 (40.26) | 411 (41.68) | 1.07 (0.94 to 1.22) | 1.10 (0.96 to 1.26) |
<23.87 | 11 186 (12.09) | 127 (12.88) | 1.10 (0.91 to 1.34) | 1.14 (0.93 to 1.40) |
23.87–102.90 | 11 161 (12.06) | 120 (12.17) | 1.04 (0.86 to 1.27) | 1.09 (0.88 to 1.34) |
>102.90 | 14 901 (16.11) | 164 (16.63) | 1.07 (0.90 to 1.27) | 1.08 (0.90 to 1.30) |
Test for trend | 1.01 (0.97 to 1.04) | 1.01 (0.97 to 1.05) |
*Controls were individually matched to cases on age and sex.
†Models adjusted for SES and residential location.
‡Cumulative estimated exposure = [(level of exposure)*(probability of exposure)/100]*(days employed).
ALS, amyotrophic lateral sclerosis; aOR, adjusted OR; SES, socioeconomic status.